Tag Archive for: ISA Pharmaceuticals

ISA Pharmaceuticals to Present Pre-clinical Data on its Protective SLP Therapy Against SARS-CoV-2 at the CIMT Annual Meeting

/in

Oegstgeest, The Netherlands, 27 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be presenting data evaluating the response to its T cell inducing SLP therapy against SARS-CoV-2 in collaboration with the Leiden University Medical Center (LUMC) and […]

Read more

ISA Pharmaceuticals to Attend and Present at Upcoming Scientific and Business Conferences in May and June of 2023

/in

Oegstgeest, The Netherlands, 20 April 2023 – ISA Pharmaceuticals, B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, is pleased to announce that it will be participating and presenting in person, at the following scientific and business conferences in May and June of 2023. ISA’s versatile synthetic long peptide (SLP®) […]

Read more

Optimum’s clients are at the forefront of Cancer research

/in

  World Cancer Day is a moment when all of us stop and think of the impact that cancer has on our lives. As the second-leading cause of death worldwide, with 10 million people dying from cancer every year, cancer is a very present healthcare threat. [tag] Macmillan Cancer Support estimates that there are currently […]

Read more

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

/in

─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in rare ocular cancer to be conducted at MD Anderson Cancer Center─ Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with […]

Read more